^
    Back
    Association details:
    Biomarker:AFP elevation
    Cancer:Hepatocellular Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Gastroenterol
    Title:

    Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

    Published date:
    03/30/2023
    Excerpt:
    This prospective multicenter study enrolled 70 patients with uHCC who received atezolizumab and bevacizumab (Atez/Bev)….Multivariate analysis identified high pretreatment OPN and high α-fetoprotein levels as independent predictors of PD.
    DOI:
    10.1007/s00535-023-01985-w